10.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA Nivolumab plus Ipilimumab reduced the risk of death by 37% versus standard of care, Sunitinib, in intermediate- and poor-risk patients. The combination also significantly improved overall survival in all randomized patients.
07.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA Nivolumab plus Ipilimumab showed superior overall survival versus current standard of care sunitinib in intermediate- and poor-risk patients, a co-primary endpoint. The combination also met the secondary endpoint of improved overall survival in all randomized patients